Kendall Shultes

Jun 14, 2024 | nature.com | Rachel Gilmore |Bhagirathbhai Dholaria |Reena V. Jayani |Bipin N. Savani |Kendall Shultes |Dwight D. Eplin

AbstractThe age effect in severe aplastic anemia (SAA) following allogeneic hematopoietic cell transplantation (HCT) favors the use of reduced intensity conditioning (RIC) regimens in older adults. We implemented a non-myeloablative regimen consisting of fludarabine, cyclophosphamide, and rituximab (FCR) to improve HCT outcomes in SAA. Patients who underwent first HCT for SAA utilizing an FCR regimen between January 2016 and May 2022 were included.